Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHI NASDAQ:CWBR NASDAQ:REVB NASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.81+1.7%$1.62$1.20▼$3.35$5.90M0.95105,183 shs338,470 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AREVBRevelation Biosciences$2.33-17.4%$2.67$2.11▼$60.48$4.79M-0.0479,598 shs1.15 million shsTCRTAlaunos Therapeutics$2.30+5.0%$2.96$1.31▼$6.20$4.83M-0.82338,151 shs27,612 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma+6.21%+27.90%+19.80%+10.99%-89.96%CWBRCohBar0.00%0.00%0.00%0.00%-4.65%REVBRevelation Biosciences-1.74%+2.17%+18.49%+11.96%-93.25%TCRTAlaunos Therapeutics+1.39%+2.82%-11.34%-32.20%-9.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.81+1.7%$1.62$1.20▼$3.35$5.90M0.95105,183 shs338,470 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AREVBRevelation Biosciences$2.33-17.4%$2.67$2.11▼$60.48$4.79M-0.0479,598 shs1.15 million shsTCRTAlaunos Therapeutics$2.30+5.0%$2.96$1.31▼$6.20$4.83M-0.82338,151 shs27,612 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma+6.21%+27.90%+19.80%+10.99%-89.96%CWBRCohBar0.00%0.00%0.00%0.00%-4.65%REVBRevelation Biosciences-1.74%+2.17%+18.49%+11.96%-93.25%TCRTAlaunos Therapeutics+1.39%+2.82%-11.34%-32.20%-9.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.40M1.34N/AN/A$0.70 per share2.59CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ATCRTAlaunos Therapeutics$10K508.30N/AN/A$1.29 per share1.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AREVBRevelation Biosciences-$15.04M-$68.61N/AN/AN/AN/A-240.27%-148.95%11/14/2025 (Estimated)TCRTAlaunos Therapeutics-$4.68M-$2.46N/A∞N/AN/A-168.02%-121.37%11/12/2025 (Estimated)Latest CWBR, TCRT, REVB, and CPHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TCRTAlaunos Therapeutics-$5.3340-$0.63+$4.7040-$0.63N/AN/A8/7/2025Q2 2025REVBRevelation Biosciences-$4.46-$7.01-$2.55-$7.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26CWBRCohBarN/AN/AN/AREVBRevelation BiosciencesN/A3.423.42TCRTAlaunos TherapeuticsN/A3.483.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/ACWBRCohBar2.47%REVBRevelation Biosciences12.80%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma17.32%CWBRCohBar6.51%REVBRevelation Biosciences2.30%TCRTAlaunos Therapeutics16.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableCWBRCohBar102.91 millionN/ANot OptionableREVBRevelation Biosciences101.70 million1.66 millionNot OptionableTCRTAlaunos Therapeutics402.21 million1.85 millionNo DataCWBR, TCRT, REVB, and CPHI HeadlinesRecent News About These CompaniesAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market ImplicationsAugust 12, 2025 | msn.comAlaunos Therapeutics Appoints Holger Weis as New CEOJuly 25, 2025 | theglobeandmail.comAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comAlaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comAlaunos Therapeutics Amends Warrant Agreement with Mast HillJune 10, 2025 | tipranks.comPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)May 14, 2025 | globenewswire.comAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comPrecigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAfter axing its sole clinical prospect last year, Alaunos cuts ties with PrecigenOctober 11, 2024 | fiercebiotech.comFAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comTCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024May 15, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, TCRT, REVB, and CPHI Company DescriptionsChina Pharma NYSE:CPHI$1.81 +0.03 (+1.74%) Closing price 03:59 PM EasternExtended Trading$1.81 0.00 (-0.22%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.CohBar NASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Revelation Biosciences NASDAQ:REVB$2.33 -0.49 (-17.38%) Closing price 04:00 PM EasternExtended Trading$2.54 +0.21 (+9.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Alaunos Therapeutics NASDAQ:TCRT$2.30 +0.11 (+5.02%) Closing price 04:00 PM EasternExtended Trading$2.31 +0.01 (+0.22%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
